Wide Ranks

COGT

Cogent Biosciences, Inc.

9.58

Top Statistics
Market Cap 1 B Forward PE -4.21 Revenue Growth 0.00 %
Current Ratio 6.44 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.30 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 335 M Total Cash Per Share 3.04 Total Debt 17 M
Total Debt To Equity 5.67 Current Ratio 6.44 Book Value Per Share 1.85
All Measures
Short Ratio 609.00 % Message Board Id finmb_675599465 Shares Short Prior Month 8 M
Return On Equity -0.7847 City Waltham Uuid 3a4634b7-b227-3bef-b8b4-12fa6851bf14
Previous Close 9.62 First Trade Date Epoch Utc 1 B Book Value 1.85
Beta 0.0210 Total Debt 17 M Volume 2 M
Price To Book 5.19 Last Split Date 1 B Fifty Two Week Low 3.67
Total Cash Per Share 3.04 Shares Short Previous Month Date 1 B Target Median Price 16.00
Max Age 86400 Recommendation Mean 1.73 Sand P52 Week Change 0.3133
Target Mean Price 16.36 Net Income To Common -242296992 Short Percent Of Float 0.0773
Implied Shares Outstanding 110 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Total Cash 335 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0012 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 9.62
Target Low Price 10.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 10.76
Open 9.73 Free Cashflow -101876624 State MA
Dividend Yield 0.00 % Return On Assets -0.4402 Time Zone Short Name EST
Trailing Eps -2.48 Day Low 9.45 Address1 275 Wyman Street
Shares Outstanding 110 M Price Hint 2 Target High Price 23.00
Website https://www.cogentbio.com 52 Week Change 0.2490 Average Volume 1 M
Forward Eps -2.30 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 632.50 % Last Split Factor 1:4 Regular Market Day High 9.99
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 5.67
Fifty Two Week High 12.61 Day High 9.99 Shares Short 7 M
Regular Market Open 9.73 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0699 Operating Cashflow -191284000
Currency USD Time Zone Full Name America/New_York Market Cap 1 B
Is_nasdaq_100 False Zip 02451 Quote Type EQUITY
Industry Biotechnology Long Name Cogent Biosciences, Inc. Regular Market Day Low 9.45
Held Percent Institutions 1.11 Current Price 9.58 Address2 3rd Floor
Enterprise To Ebitda -3.30 Financial Currency USD Current Ratio 6.44
Industry Disp Biotechnology Number Of Analyst Opinions 11 Country United States
Float Shares 70 M Two Hundred Day Average 8.87 Enterprise Value 851 M
Forward PE -4.21 Regular Market Volume 2 M Ebitda -258010000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases.

Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.

The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib.

The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020.

Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.